Category: Respiratory
-
RevealDx wins FDA clearance for lung nodule assessment software
New AI software aims to help radiologists assess lung nodule cancer risk and improve early detection.
-
Regeneron and Tessera ink $275 mil pact for gene editing therapy
The companies will co-develop TSRA-196, a potential one-time genetic treatment for alpha-1 antitrypsin deficiency.
-
Nektar’s Treg therapy shows promise in dermatitis and asthma
Treg-targeting biologic, rezpegaldesleukin (Rezpeg), demonstrates significant improvement in asthma control for patients with atopic dermatitis.
-
FDA grants breakthrough status to Cidara’s flu drug
Cidara Therapeutics’ CD388, a long-acting influenza prophylactic, has previously received funding worth up to $339 million from the US BARDA.
-
Synchrony Medical launches LibAirty airway clearance system in the US
The FDA-cleared at-home system is designed to assist people living with chronic lung diseases such as chronic obstructive pulmonary disease (COPD), bronchiectasis, and cystic fibrosis.
-
ERS 2025: Boehringer shares additional data for lung fibrosis therapy
Pooled Phase III data show nerandomilast may reduce death risk in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).
-
PureTech’s deupirfenidone: Overcoming the efficacy paradigm in IPF
PureTech’s Camilla Graham talks about the IPF landscape, barriers to antifibrotic use, and the development of deupirfenidone.
-
PureTech forms spins out Celea Therapeutics to advance fibrosis therapy
Celea Therapeutics’ lead candidate is a Phase III-ready dupirfenidone, following strong Phase IIb results in idiopathic pulmonary fibrosis (IPF).
-
Ethris starts Phase IIa trial for mRNA therapy targeting asthma triggers
First patient dosed in UK study testing intranasal mRNA therapy to prevent asthma flare-ups caused by viral infections.
-
Cereno’s IPF drug clears Phase I, paving way for Phase II
The company plans to start Phase II trial for HDAC inhibitor CS014 as a treatment for idiopathic pulmonary fibrosis (IPF) in H1 2026.
-
Ethris and Thermo Fisher partner to advance mRNA therapeutics
Ethris teams up with Thermo Fisher to scale next-gen mRNA tech, advancing its asthma candidate, ETH47, into Phase II trials in 2025.
-
Cereno wins FDA endorsement for Phase IIb trial of PAH drug
Following the Type C meeting with the US FDA, the company plans to start the Phase IIb trial in PAH in the first half of 2026.
Latest posts
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
The risks and rewards of biomarker-based surrogates are crucial for optimizing clinical trial outcomes and guiding effective treatments.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Promis reports first human evidence of aβ oligomer reduction by pmn310
PMN310 demonstrates dose-dependent reduction of amyloid-beta oligomers in human CSF, marking a key milestone in Alzheimer’s treatment development.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.